KR20080080482A - 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 - Google Patents

독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 Download PDF

Info

Publication number
KR20080080482A
KR20080080482A KR1020087008184A KR20087008184A KR20080080482A KR 20080080482 A KR20080080482 A KR 20080080482A KR 1020087008184 A KR1020087008184 A KR 1020087008184A KR 20087008184 A KR20087008184 A KR 20087008184A KR 20080080482 A KR20080080482 A KR 20080080482A
Authority
KR
South Korea
Prior art keywords
adc
amino acid
cdr3
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087008184A
Other languages
English (en)
Korean (ko)
Inventor
마이클 에스 킨치
헤렌 우
크리스틴 바시
데이빗 타이스
창서우 가오
피터 디 센터
Original Assignee
메디뮨 엘엘씨
시애틀 지네틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨, 시애틀 지네틱스, 인크. filed Critical 메디뮨 엘엘씨
Publication of KR20080080482A publication Critical patent/KR20080080482A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020087008184A 2005-09-07 2006-09-07 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 Ceased KR20080080482A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71436205P 2005-09-07 2005-09-07
US60/714,362 2005-09-07
US73596605P 2005-11-14 2005-11-14
US60/735,966 2005-11-14

Publications (1)

Publication Number Publication Date
KR20080080482A true KR20080080482A (ko) 2008-09-04

Family

ID=37836475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087008184A Ceased KR20080080482A (ko) 2005-09-07 2006-09-07 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체

Country Status (7)

Country Link
US (2) US20090304721A1 (enExample)
EP (1) EP1928912A4 (enExample)
JP (1) JP2009506790A (enExample)
KR (1) KR20080080482A (enExample)
AU (1) AU2006287416A1 (enExample)
CA (1) CA2621502A1 (enExample)
WO (1) WO2007030642A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140035393A (ko) * 2011-05-08 2014-03-21 주식회사 레고켐 바이오사이언스 단백질-활성제 접합체 및 이의 제조 방법
KR20140122167A (ko) * 2011-04-21 2014-10-17 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
ES2673822T3 (es) * 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
HUE036490T2 (hu) 2007-06-15 2018-07-30 Medigene Ag Tumorok kezelése anti-L1 antitest alkalmazásával
CN106432496B (zh) 2007-07-16 2020-02-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
AR067543A1 (es) 2007-07-16 2009-10-14 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
WO2009087462A2 (en) * 2007-12-24 2009-07-16 Oxford Biotherapeutics Ltd. Ephrin type-a receptor 10 protein
EP2247620B1 (en) 2008-01-31 2016-05-18 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
TWI504410B (zh) 2010-02-08 2015-10-21 Agensys Inc 結合至１６１ｐ２ｆ１０ｂ蛋白之抗體藥物結合物（ａｄｃ）
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
RU2598711C2 (ru) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
PT2648752T (pt) 2010-12-06 2017-03-28 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP3608340A1 (en) 2011-11-23 2020-02-12 Medlmmune, LLC Binding molecules specific for her3 and uses thereof
WO2013084147A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
US20130273029A1 (en) 2011-12-05 2013-10-17 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
EP2855520B1 (en) 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
KR20150030724A (ko) * 2012-07-13 2015-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｃａｒ ｔ 세포를 조절하기 위한 조성물 및 방법
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2014124316A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
EP2970453B1 (en) * 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
EA035253B1 (ru) 2013-03-15 2020-05-21 Новартис Аг Лекарственные конъюгаты антител
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
SG11201605449YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
EA201691827A1 (ru) 2014-03-12 2017-01-30 Новартис Аг Конкретные участки для модификации антител с целью получения иммуноконъюгатов
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
RU2708075C2 (ru) 2014-04-30 2019-12-04 Пфайзер Инк. Конъюгаты анти-ртк7 антитело-лекарственное средство
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
CA2954041A1 (en) * 2014-07-11 2016-01-14 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
BR112017001588A2 (pt) 2014-08-12 2017-11-21 Novartis Ag conjugados de anticorpo/fármaco anti-cdh6
CN112546238A (zh) * 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
SI3262071T1 (sl) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Način uporabe imunokonjugatov proti CD79b
JP6875275B2 (ja) 2014-09-30 2021-05-19 ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ Ｌ１ｃａｍ（ｃｄ１７）と結合する抗体などの結合分子
WO2016055907A1 (en) * 2014-10-10 2016-04-14 Pfizer Inc. Synergistic auristatin combinations
SI3215518T1 (sl) 2014-10-29 2021-08-31 Bicyclerd Limited Biciklični peptidni ligandi, značilni za MT1-MMP
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
EP3221351B1 (en) * 2014-11-19 2024-11-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
MA55746A (fr) 2016-01-21 2022-03-02 Novartis Ag Molécules multispécifiques ciblant cll-1
MA45324A (fr) * 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018069289A1 (en) 2016-10-11 2018-04-19 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3041254A1 (en) 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
KR102312222B1 (ko) 2016-12-22 2021-10-12 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US11517567B2 (en) 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
EP4085919A3 (en) 2017-07-21 2023-02-08 Novartis AG Compositions and methods to treat cancer
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
EP4116327A1 (en) 2017-10-11 2023-01-11 Board Of Regents, The University Of Texas System Human pd-l1 antibodies and methods of use therefor
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
EP3712170A4 (en) * 2017-11-10 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. CD96 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
WO2019162682A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
JP7390301B2 (ja) 2018-03-23 2023-12-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトｐｄ－ｌ２抗体およびその使用方法
AU2019239568B2 (en) 2018-03-23 2025-09-11 Board Of Regents, The University Of Texas System Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
SG11202010469QA (en) 2018-05-23 2020-11-27 Adc Therapeutics Sa Molecular adjuvant
IL316090A (en) 2018-06-01 2024-12-01 Eisai R&D Man Co Ltd Antibody-drug conjugates of splicing modulators and methods of use
IL322895A (en) 2018-06-05 2025-10-01 King S College London Btnl3/8-targeted constructs for delivery of cargo to the digestive system
EP3801635A4 (en) * 2018-06-07 2022-04-06 Magenta Therapeutics, Inc. THERAPEUTIC METHODS USING ANTIBODY-DRUG CONJUGATE (ADC)
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
WO2020076849A1 (en) 2018-10-11 2020-04-16 The Scripps Research Institute Antibody compounds with reactive arginine and related antibody drug conjugates
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
PH12021551389A1 (en) 2018-12-13 2022-05-16 Eisai R&D Man Co Ltd Herboxidiene antibody-drug conjugates and methods of use
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
CR20210324A (es) 2018-12-21 2021-07-14 Novartis Ag Anticuerpos anti-pmel 17 y conjugados de los mismos
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
EP3970752A1 (en) 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
WO2022112942A2 (en) 2020-11-24 2022-06-02 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4301785A4 (en) 2021-03-05 2025-04-23 Atreca, Inc. EPHA2 ANTIBODIES
JP2024517409A (ja) 2021-04-16 2024-04-22 ノバルティス アーゲー 抗体薬物結合体及びその作成方法
KR20230060546A (ko) 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
EP4480498A1 (en) 2022-02-17 2024-12-25 NOVELTY NOBILITY Inc. Antibody-drug conjugate
AU2023271885A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
EP4525927A1 (en) 2022-05-20 2025-03-26 Novartis AG Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
KR20250160354A (ko) 2023-03-10 2025-11-12 노파르티스 아게 Panras 억제제 항체-약물 콘쥬게이트 및 이의 사용 방법
WO2024219894A1 (ko) 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140122167A (ko) * 2011-04-21 2014-10-17 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
KR20140035393A (ko) * 2011-05-08 2014-03-21 주식회사 레고켐 바이오사이언스 단백질-활성제 접합체 및 이의 제조 방법

Also Published As

Publication number Publication date
WO2007030642A2 (en) 2007-03-15
US20090304721A1 (en) 2009-12-10
JP2009506790A (ja) 2009-02-19
US20110280892A1 (en) 2011-11-17
EP1928912A4 (en) 2010-02-24
EP1928912A2 (en) 2008-06-11
AU2006287416A1 (en) 2007-03-15
WO2007030642A3 (en) 2007-10-11
CA2621502A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
KR20080080482A (ko) 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
CA2919790C (en) Anti-cxcr4 antibodies and antibody-drug conjugates
KR102100467B1 (ko) Ｃｄ33 항체 및 암을 치료하기 위한 이의 용도
CA2939492C (en) Anti-human cd52 immunoglobulins
JP4414142B2 (ja) 特異的結合タンパク質およびその使用
KR101783529B1 (ko) 항체-약물 접합체
CA2947148C (en) Anti-ptk7 antibody-drug conjugates
ES2625798T3 (es) Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
RU2739617C2 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3
US20160194402A1 (en) Cd70-binding peptides and method, process and use relating thereto
KR20170038835A (ko) 이특이적 her2 및 cd3 결합 분자
JP2017506217A (ja) 標的ＴＧＦβ阻害
CA2711736A1 (en) Cysteine engineered antibodies for site-specific conjugation
TW202116357A (zh) 抗組織因子抗體-藥物結合物及相關方法
CN110352202A (zh) 抗pd-l1抗体和il-7融合蛋白
CN115038720B (zh) 抗gprc5d单克隆抗体及其用途
KR20250050936A (ko) 세포독성 화합물 및 이의 접합체
CN105828841A (zh) 抗-efna4抗体-药物缀合物
CN101309933A (zh) 毒素偶联的Eph受体抗体
CN109195626B (zh) 结合死亡受体4和死亡受体5的抗体
HK1125655A (en) Toxin conjugated eph receptor antibodies
HK40080157B (zh) 抗gprc5d单克隆抗体及其用途
WO2025157214A1 (zh) 抗FGFR2b抗体及抗体药物偶联物
TW202543679A (zh) 一種免疫綴合物及其用途
HK1229353A1 (en) Anti-cxcr4 antibodies and antibody-drug conjugates

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080404

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110907

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130409

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130614

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130409

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I